問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



China Medical University Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 2,076

    Total Beds

  • 884

    Total Doctors

  • ctcadm.cmuh@gmail.com
  • Clinical Trial Center
  • 04-22052121#1471~1485
  • 404Taichung CityTaichung NorthNo. 2, Yude Rd., North Dist., Taichung City 404332, Taiwan (R.O.C.)

Recruiting Trial

785Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1858Cases

2015-08-17 - 2018-02-28

Phase III

A Randomized, Double-Blind, Double-Dummy, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of Oral Once-Daily Administration of TAK-438 10 or 20 mg Compared to Lansoprazole 15 mg in the Maintenance Treatment of Subjects With Endoscopic Healing of Erosive Esophagitis

  • Condition/Disease

    Erosive Esophagitis

  • Test Drug

    TAK-438

Participate Sites
14Sites

Terminated12Sites

邱正堂
Linkou Chang Gung Medical Foundation

Digestive System Department

吳登強
Kaohsiung Municipal Gangshan Hospital

未分科

2014-12-01 - 2018-06-30

Phase II

A Randomized Phase 2A/2B, Multicenter Study to Compare the Efficacy and Safety of ASLAN001 in Combination with Capecitabine to Lapatinib in Combination with Capecitabine in Patients with HER-2-Positive Metastatic Breast Cancer that has Failed on Prior Trastuzumab Therapy

  • Condition/Disease

    Breast Cancer

  • Test Drug

    ASLAN001

Participate Sites
7Sites

Terminated6Sites

Study ended1Sites

王惠暢
China Medical University Hospital

Division of General Surgery

2016-09-01 - 2019-01-31

Phase III

A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy

  • Condition/Disease

    Rheumatoid Arthritis

  • Test Drug

    Olokizumab

Participate Sites
5Sites

Terminated3Sites

Study ended1Sites

黃春明
China Medical University Hospital

2016-05-01 - 2018-09-30

Phase III

A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro esophageal junction

  • Condition/Disease

    Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

  • Test Drug

    avelumab

Participate Sites
10Sites

Terminated9Sites

陳仁熙
Linkou Chang Gung Medical Foundation

白禮源
China Medical University Hospital-Taipei

未分科

2015-10-01 - 2022-06-22

Phase III

A Phase III, open-label, multicenter trial of avelumab (MSB0010718C) versus platinum-based doublet as a first-line treatment of recurrent or Stage IV PD-L1+ non–small-cell lung cancer

  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    Avelumab

Participate Sites
7Sites

Terminated7Sites

2016-02-01 - 2019-01-16

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated3Sites

2015-11-01 - 2026-12-31

Phase III

A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy

  • Condition/Disease

    Prostate Cancer

  • Test Drug

    Enzalutamide (formerly MDV3100)

Participate Sites
9Sites

Terminated7Sites

黃書彬
Kaohsiung Municipal Gangshan Hospital

未分科

林永昌
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2015-10-01 - 2017-02-15

Phase III

A Phase III open-label, multicenter trial of avelumab (MSB0010718C) as a third-line treatment of unresectable, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma

  • Condition/Disease

    unresectable, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma

  • Test Drug

    Avelumab

Participate Sites
7Sites

Terminated5Sites

Study ended1Sites

2015-11-01 - 2018-04-30

Phase IV

A 26 week, randomized, active-controlled safety study of double-blind formoterol fumarate in free combination with an inhaled corticosteroid versus an inhaled corticosteroid in adolescent and adult patients with persistent asthma

  • Condition/Disease

    Asthma

  • Test Drug

    Foradil®Aerolizer®

Participate Sites
2Sites

Terminated1Sites

2009-09-01 - 2013-09-30

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

1 141 142 143 144 145 186
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB